ABSTRACT
The impact of pretransplant T-cell sensitivity testing using carboxylfluorescein diacetate succinimidyl ester (CFSE)-based flow cytometry was studied in 32 patients with chronic renal failure. There was considerable interindividual variation in the inhibitory effects of cyclosporine (CSA), tacrolimus (TAC), and prednisolone (PRD) but only a small amount of interindividual variation for mycophenolic acid (MPA). Patients with high sensitivity to CSA tended to experience viral reactivation. In addition to post-transplant blood-level monitoring, pretransplant pharmacodynamics could provide useful information on optimal and safe immunosuppressive therapy.
Subject(s)
Fluoresceins , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation/immunology , Succinimides , T-Lymphocytes/drug effects , Adult , Cell Proliferation/drug effects , Cyclosporine/pharmacokinetics , Cyclosporine/pharmacology , Female , Fluorescent Dyes , Humans , Kidney Failure, Chronic/surgery , Male , Middle Aged , Prednisolone/pharmacokinetics , Prednisolone/pharmacology , Prospective Studies , T-Lymphocytes/immunology , Tacrolimus/pharmacokinetics , Tacrolimus/pharmacologySubject(s)
Epilepsies, Partial/blood , Valproic Acid/pharmacokinetics , Adolescent , Adult , Child , Circadian Rhythm , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Administration Schedule , Epilepsies, Partial/drug therapy , Humans , Male , Valproic Acid/administration & dosageABSTRACT
In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy. Adriamycin (ADM), Mitomycin C (MMC), 5-FU and Lipiodol (LPD) were administered an average of 13.5 times over a mean period of 106 days. Except for 5 unevaluable cases, there were 0 CR, 5 PR, 4 MR, 7 NC and 2 PD cases, for an efficiency rate of 27.8%. Complications thought to be due to the catheter included catheter blockade in 1 case (4.3%) and dermal infection of insertion site in 3 cases (13.0%). As for the results of follow-up study, one-year survival rate with this therapy was 47.8%, which compares favorably with a one-year survival rate of 30.0% in 30 cases treated only with TAE. From the above results, hepatic arterial infusion chemotherapy can be repeatedly performed on an outpatient basis, and it is considered to be a useful therapeutic method for treating unresectable hepatocellular carcinoma.
